IPO registrations (S-1, F-1) · Registrants
Ginkgo Bioworks Holdings, Inc.
- SEC CIK
- 1830214 · filings on EDGAR ↗
- Former names
- Soaring Eagle Acquisition Corp. (2020–2021); Spinning Eagle Acquisition Corp. (2020–2021)
- Registration
- Form S-1, first filed 2020-12-23, last 2022-09-27; 5 initial registrations, 8 amendments
- Outcome
- Final prospectus filed 2021-02-25; declared effective 2021-02-23
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 27 DRYDOCK AVENUE, 8TH FLOOR, Boston, MA 02210
- EIN
- 87-2652913
- Ticker
- DNA (NYSE)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Ginkgo Bioworks Holdings, Inc. on the corporate pages
Offering terms
- Final price
- $10.00 per ADS (424B4 filed 2021-02-25, an initial public offering)
- Shares sold
- 150,000,000
- Gross proceeds
- $1,500,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol SRNG
- Lead underwriters
- Goldman Sachs (150,000,000 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: GINKGO BIOWORKS HOLDINGS, INC. Fuzzy (name and state)
- SEC filer: Ginkgo Bioworks Holdings, Inc. EXACT (CIK (EXACT))
- Person page: Ole Andreas Halvorsen Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 35
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-12-23 | S-1 | S-1 (registration) | Spinning Eagle Acquisition Corp. | 0001193125-20-326138 ↗ |
| 2021-01-04 | S-1/A | S-1/A (amendment) | Spinning Eagle Acquisition Corp. | 0001193125-21-001119 ↗ |
| 2021-02-11 | S-1/A | S-1/A (amendment) | Soaring Eagle Acquisition Corp. | 0001193125-21-038397 ↗ |
| 2021-02-12 | S-1/A | S-1/A (amendment) | Soaring Eagle Acquisition Corp. | 0001193125-21-039667 ↗ |
| 2021-02-22 | S-1/A | S-1/A (amendment) | Soaring Eagle Acquisition Corp. | 0001193125-21-049766 ↗ |
| 2021-02-23 | EFFECT | EFFECT (declared effective) | Soaring Eagle Acquisition Corp. | 9999999995-21-000712 ↗ |
| 2021-02-25 | 424B4 | 424B4 (final prospectus) | Soaring Eagle Acquisition Corp. | 0001193125-21-056976 ↗ |
| 2021-08-11 | S-1 | S-1 (registration) | Soaring Eagle Acquisition Corp. | 0001193125-21-243355 ↗ |
| 2021-08-11 | EFFECT | EFFECT (declared effective) | Soaring Eagle Acquisition Corp. | 9999999995-21-003147 ↗ |
| 2021-09-15 | S-1/A | S-1/A (amendment) | Soaring Eagle Acquisition Corp. | 0001193125-21-273556 ↗ |
| 2021-09-16 | S-1/A | S-1/A (amendment) | Soaring Eagle Acquisition Corp. | 0001193125-21-274716 ↗ |
| 2021-09-16 | EFFECT | EFFECT (declared effective) | Soaring Eagle Acquisition Corp. | 9999999995-21-003561 ↗ |
| 2021-09-20 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-21-003585 ↗ |
| 2021-11-24 | S-1 | S-1 (registration) | Ginkgo Bioworks Holdings, Inc. | 0001193125-21-338776 ↗ |
| 2021-12-10 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-21-004649 ↗ |
| 2022-03-31 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-000782 ↗ |
| 2022-03-31 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-000789 ↗ |
| 2022-04-05 | S-1 | S-1 (registration) | Ginkgo Bioworks Holdings, Inc. | 0001193125-22-095380 ↗ |
| 2022-04-12 | S-1/A | S-1/A (amendment) | Ginkgo Bioworks Holdings, Inc. | 0001193125-22-103029 ↗ |
| 2022-05-03 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-001289 ↗ |
| 2022-09-07 | S-1 | S-1 (registration) | Ginkgo Bioworks Holdings, Inc. | 0001193125-22-240046 ↗ |
| 2022-09-08 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-002618 ↗ |
| 2022-09-08 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-002619 ↗ |
| 2022-09-08 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-002622 ↗ |
| 2022-09-14 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-002705 ↗ |
| 2022-09-27 | S-1/A | S-1/A (amendment) | Ginkgo Bioworks Holdings, Inc. | 0001193125-22-252186 ↗ |
| 2022-09-29 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-002859 ↗ |
| 2022-10-14 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-003052 ↗ |
| 2022-10-24 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-003117 ↗ |
| 2022-10-24 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-003118 ↗ |
| 2022-10-24 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-003119 ↗ |
| 2022-10-24 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-22-003122 ↗ |
| 2023-02-03 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-23-000281 ↗ |
| 2023-08-29 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-23-002526 ↗ |
| 2024-05-17 | EFFECT | EFFECT (declared effective) | Ginkgo Bioworks Holdings, Inc. | 9999999995-24-001573 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-02-22 | S-1/A | registration statement | $10.00 | 150,000,000 | $1,500,000,000 | Nasdaq SRNG | 1 | primary document; price sentence, shares headline, proceeds table, underwriting table 1, cover names 1 | document ↗ | |
| 2021-02-25 | 424B4 | final prospectus | $10.00 | 150,000,000 | $1,500,000,000 | Nasdaq SRNG | 1 | primary document; price sentence, shares headline, proceeds table, underwriting table 1, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Baker Eli | Officer | CFO, President | 1 | 2021 | |
| Eagle Equity Partners III, LLC | Director,TenPercentOwnerOther | 2 | 2021 | ||
| Kazam Joshua A | Director | 1 | 2021 | ||
| Lee Isaac | Director | 1 | 2021 | ||
| Leiweke Timothy | Director | 1 | 2021 | ||
| Miller Dennis A | Director | 1 | 2021 | ||
| PAUL LAURENCE E | Director | 1 | 2021 | ||
| ROSEN FREDRIC D | Director | 1 | 2021 | ||
| SLOAN HARRY | Director; Director,Officer | CEO, Chairman | 11 | 2021–2026 | |
| Belldegrun Arie | Director | 5 | 2021–2024 | ||
| Canton Barry | TenPercentOwner | 95 | 2021–2026 | ||
| DEKKERS MARIJN E | Director | 9 | 2021–2024 | ||
| Dmytruk Mark E. | Officer | Chief Financial Officer; See remarks; See Remarks | 45 | 2021–2025 | |
| Fallon Marie E. | Officer | Chief Accounting Officer; See remarks; See Remarks | 15 | 2021–2023 | |
| HENRY CHRISTIAN O | Director | 25 | 2021–2026 | ||
| Kelly Jason R | Director,Officer | CEO & Founder; See remarks; See Remarks | 95 | 2021–2026 | |
| Kewalramani Reshma | Director | 7 | 2021–2024 | ||
| Sankar Shyam | Director | 9 | 2021–2025 | ||
| Shetty Reshma P. | Director,Officer,TenPercentOwner | President, COO & Founder; See remarks; See Remarks | 96 | 2021–2026 | |
| HALVORSEN OLE ANDREAS | TenPercentOwner | 2 | 2021–2022 | person page Fuzzy | |
| Ott David C. | TenPercentOwner | 2 | 2021–2022 | ||
| Shabet Rose Sharon | TenPercentOwner | 2 | 2021–2022 | ||
| VIKING GLOBAL INVESTORS LP | TenPercentOwner | 2 | 2021–2022 | ||
| Viking Global Opportunities GP LLC | TenPercentOwner | 2 | 2021–2022 | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | TenPercentOwner | 2 | 2021–2022 | ||
| Viking Global Opportunities Portfolio GP LLC | TenPercentOwner | 2 | 2021–2022 | ||
| CASCADE INVESTMENT, L.L.C. | TenPercentOwner | 1 | 2021 | ||
| GATES WILLIAM H III | TenPercentOwner | 1 | 2021 | ||
| Viking Global Opportunities Parent GP LLC | TenPercentOwner | 1 | 2022 | ||
| Hannan Kathy Hopinkah | Director | 5 | 2022–2025 | ||
| Coen Steven P. | Officer | Chief Accounting Officer; See remarks | 29 | 2023–2026 | |
| Fubini Ross | Director | 4 | 2024–2026 | ||
| POTTER MYRTLE S | Director | 3 | 2024–2025 | ||
| Kosuri Sri | Director | 4 | 2024–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | GINKGO BIOWORKS HOLDINGS, INC. | MA | State business registries | name and state |
| Contractor | GINKGO BIOWORKS INC | MA | Nonprofit contractors (Form 990) | same street address and ZIP code, 27 DRYDOCK AVE 8TH FL 02210 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | Ginkgo Bioworks Holdings, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Ole Andreas Halvorsen | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MA first:
- TRANSCEND THERAPEUTICS INC MA
- Eloxx Pharmaceuticals, Inc. MA
- PANACOS PHARMACEUTICALS, INC. MA
- CHARLES RIVER LABORATORIES INC MA
- AGENUS INC MA
- CURIS INC MA
- MOMENTA PHARMACEUTICALS INC MA
- ACCELERON PHARMA INC MA
- bluebird bio, Inc. MA
- Altus Pharmaceuticals Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health